Showing 36 out of 97 results
The Healthcare Law Review - 4th Edition: Russia Chapter
Russia’s current healthcare market is characterised, on the one hand, by the dominant role of public healthcare providers operating under the state-run …
Can predictive analytics prevent employee misconduct?
The appeal of data tools in unearthing misconduct is clear. So are the risks if employers fail to tread carefullyWith predictive policing and crime …
Digital forensics in investigations and the growing data burden
Businesses will need smarter data collection and management strategies to satisfy regulators The approach to digital forensics in investigations is …
Using big data to fight financial crime
In a regulatory environment which demands ever higher standards for anti-money laundering (AML) compliance, many financial institutions have responded by …
Regulators lead businesses in monitoring of misconduct
As regulators and law enforcement increasingly rely on advanced data analytics for monitoring and surveillance, the risk is growing that they will detect …
Big data and Modern Slavery – Progress not panacea
Data analysis can only get you so far in modern slavery compliance… and regulators are watchingWhile the benefits of data and technology can be leveraged …
CJEU rules that providing free samples of non-prescription drugs to pharmacists is permitted
On 11 June, the Court of Justice of the European Union ("CJEU") ruled on the question of whether free samples to pharmacists of medicines may be supplied …
Herbert Smith Freehills advises Achilles Vaccines in record seed financing for biotech sector
Herbert Smith Freehills has advised Achilles Vaccines, a biotech company focusing on the research and development of vaccines against malaria and other …
Calls for increased domestic pharmaceutical production not warranted, say Herbert Smith Freehills experts
Increased commentary about Australia’s perceived vulnerability to pharmaceutical shortages have led to recent calls for an overhaul of the country’s …
Manufacturing medicines in Australia: examining the need for increased domestic capability
There has been much discussion about the need for Australia to increase “sovereign capability” in domestic pharmaceutical manufacturing. …
Patent and Pharma Update, May 2020
Key recent developments in the United Kingdom and Europe relating to patents and the pharmaceutical sector In this update we welcome our new IP partner …
Commonwealth fails in its claim for compensation for PBS expenditure
The Federal Court’s decision in Commonwealth v Sanofi Justice Nicholas’ long-awaited decision in Commonwealth v Sanofi is an Australian first.1 Of the 4 …
Showing 36 out of 97 results
View more